DoxoDB: A Database for the Expression Analysis of Doxorubicin-Induced lncRNA Genes

Cancer and cardiovascular disease are the leading causes of death worldwide. Recent evidence suggests that these two life-threatening diseases share several features in progression, such as angiogenesis, fibrosis, immune responses. This has led to emergence a new field called cardio-oncology. Doxorubicin is chemotherapy drug widely used treat cancer, bladder breast cancer. However, this serious side effects, including acute ventricular dysfunction, cardiomyopathy, heart failure. Based on evidence, we hypothesize comparing expression profiles cells tissues treated with doxorubicin may yield insights into adverse effects cellular activities. To test hypothesis, analyzed published RNA sequencing (RNA-seq) data from doxorubicin-treated identify commonly differentially expressed genes, long non-coding RNAs (lncRNAs) they known be dysregulated diseased cells. From our systematic analysis, identified doxorubicin-induced genes. confirm findings, human cardiac fibroblasts record changes selected genes performed loss-of-function experiment lncRNA MAP3K4-AS1. further disseminate data, built web database DoxoDB.